

\*\*\*\*Updated June 2013\*\*\*\*

## MarketVIEW: Yellow Fever vaccines (CAT: VAMV019)

<b>Product Name</b>	:	<b>MarketVIEW:</b> yellow fever vaccines
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation + 2 forecast models
<b>Therapeutic Area</b>	:	Travel/endemic vaccines
<b>Publication date</b>	:	June 2013
<b>Catalogue No</b>	:	VAMV019

## Background

Yellow Fever (YF) is a mosquito-borne disease caused by the *Amaril* virus which has symptoms that range from mild to severe illness and even death (est 30,000/yr). The disease, which exists in various forms, is mainly endemic to parts of Africa and Latin America (LATAM) where 610 million are estimated to be at risk of which 219 million are living in urban settings.

Yellow fever vaccination, using a one shot live-attenuated vaccine based on 17-D is the most important measure to control YF and has been available for decades. It is currently used in routine childhood immunization (6-9 mos) and as part of donor funded mass vaccination campaigns operated by the YF initiative (WHO/UNICEF). YF vaccine is also used by Western travelers (YF-VAX, Stamaril, Sanofi Pasteur) to endemic regions where certification is required for entry. Various militaries also use YF vaccine for troops stationed in certain areas.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Yellow Fever vaccination across endemic, travelers and military markets to 2030. The model contains value (\$ m) and volume (mio doses) predictions/with supplier volume analysis. Safety considerations of current vaccines are discussed along with new inactivated vaccines e.g. Xcellerex Inc which also have been forecasted at varying pricing levels.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Yellow Fever epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of travel and endemic vaccines has also been utilised.

### PRODUCT CONTENTS:

Updated June 2013 (CAT No: VAMV019)

\*\*\*\*This product is composed of a model and summary presentation

#### Contents – Summary presentation (MS PowerPoint based)

Author's note

Executive Summary

Yellow Fever vaccines: total value (\$m) ) – premium price

Yellow Fever vaccines: total value (\$m) ) – parity price

Yellow Fever vaccines: total volume (000s doses)

Yellow Fever vaccines: volume by market segment (000s)

Yellow Fever vaccines: value by market segment (\$m) – premium price

Yellow Fever vaccines: travel market value by vaccine (\$m) – premium price

Yellow Fever vaccines: military market value by vaccine (\$m) – premium price

Yellow Fever vaccines: value by market segment (\$m) – parity price

Yellow Fever vaccines: travel market value by vaccine (\$m) – parity price

Yellow Fever vaccines: military market value by vaccine (\$m) – parity price

Population segments modelled

Routine infant immunization: model assumptions

Mass preventive campaigns: model assumptions

Travel market (Western): model assumptions

Military market (US): model assumptions

Novel Yellow Fever vaccines: model assumptions

Novel Yellow Fever vaccines: pricing assumptions

Yellow Fever vaccine opportunity: target product profile

Yellow Fever risk areas

Yellow Fever vaccines

SAGE updated vaccine recommendations

Yellow Fever live vaccines: adverse events

Routine childhood immunization: national policies

Preventive vaccine campaigns

Travel market: North America/Europe

Military market (US): model assumptions

Novel Yellow Fever vaccines: model assumptions

Yellow Fever vaccine opportunity: target product profile

Yellow Fever risk areas

Yellow Fever vaccines

SAGE updated vaccine recommendations

Yellow Fever live vaccines: adverse events

**Continued.....**

Routine childhood immunization: national policies  
Preventive vaccine campaigns  
Travel market: North America/Europe  
Military market (US)  
Yellow Fever vaccines: global supply  
Novel Yellow Fever vaccines  
Bibliography  
About VacZine Analytics  
Disclaimer

**PAGES: 62 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand model(s) (MS Excel-based) – 2 models**

Title sheet  
Scenario definitions  
Charts value  
Charts volume  
All value (live and inact)  
All volume (live and inact)  
Travel value (live and inact)  
Travel volume (live and inact)  
Mass campaigns value (live)  
Mass campaigns of volume (live)  
Infant value (live)  
Infant (liv volume)  
Nigeria (infant)  
DRC (infant)  
Ghana (infant)  
Niger (infant)  
Burkina Faso (infant)  
Mali (infant)  
Cote D'ivore (infant)  
Angola (infant)  
Angola (infant)  
Cameroon (infant)  
Senegal (infant)  
Kenya (infant)  
Africa other (infant)  
Africa infant (new)  
Uganda (infant)  
South Sudan (infant)  
Equatorial Guinea (infant)  
LATAM infant (existing)  
Brazil  
Other LATAM  
Mass campaigns  
Nigeria  
South Sudan.  
DRC  
Congo  
Gabon  
Chad



**Continued.....**

Uganda.  
Brazil  
Travel and Military =>  
US and Canada  
Europe  
US military  
Source material =>  
Births  
Total population  
Model inputs  
Price summary  
Campaigns-Africa  
YFV coverage (WHO)  
YFV coverage (official)  
YF incidents  
Brazil NIP  
Trips (base data)  
Trips (grouped)  
Travel market variables  
Back-page

**WORKSHEETS: ~65**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £5995.00 (Region license)\*


\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

1. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 – conclusions and recommendations. WHO Weekly epidemiological report. No. 20, 2013, 88, 201–216.
2. UNICEF. Yellow fever vaccine industry consultation meeting. June 27, 2012. Available at: [http://www.unicef.org/supply/files/Yellow\\_fever\\_presentation\\_FINAL.pdf](http://www.unicef.org/supply/files/Yellow_fever_presentation_FINAL.pdf). Accessed: June 2013
3. WHO. Yellow Fever Initiative. Providing an opportunity of a lifetime. [www.who.int/csr/disease/yellowfev/brochure/en/index.html](http://www.who.int/csr/disease/yellowfev/brochure/en/index.html). Accessed: June 2013.
4. WHO. Yellow fever in Africa and South America, 2006. Weekly Epidemiological Record. 2008;83(8):60-76
5. World Tourism Organisation (WTO). Available at: <http://www.e-unwto.org>. Accessed March 2013
6. Cabada MM et al. Pre-travel preparation for Cusco, Peru: a comparison between European and North American travelers. J Travel Med. 2010 Nov-Dec;17(6):382-6
7. Jentes ES et al. Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009-2011. Am J Trop Med Hyg. 2013 May;88(5):954-961
8. Main Street Vaccines/Sanofi Pasteur Agreement. Effective June 1, 2009. Available at: [www.mainstreetvacs.com/Main\\_Street\\_Sign\\_Up\\_sheet\\_-\\_2008-2009\\_\\_3\\_1.pdf](http://www.mainstreetvacs.com/Main_Street_Sign_Up_sheet_-_2008-2009__3_1.pdf). Accessed: June 2013
9. Khromava AY., et al. Yellow Fever vaccine: An updated assessment of advanced age as a risk factor for serious Events. Vaccine 23 (2005) 3256-3263
10. MILVAX. August 2008. Available at: <http://www.vaccines.mil/documents/891PriceList.xls>. Accessed: June 2013.
11. WHO. YF reported cases (updated October 2012). Available at: [http://apps.who.int/immunization\\_monitoring/data/data\\_subject/en/index.html](http://apps.who.int/immunization_monitoring/data/data_subject/en/index.html). Accessed: June 2013.
12. WHO. Country list. April 2012. Yellow fever vaccination requirements and recommendations; and malaria situation. Available at: [www.who.int/ith/chapters/ith2012en\\_countrylist.pdf](http://www.who.int/ith/chapters/ith2012en_countrylist.pdf). Accessed: May 2013.
13. Yellow fever. Fact sheet N°100. May 2013. Available at: <http://www.who.int/mediacentre/factsheets/fs100/en/> Accessed: June 2013.
14. WHO. Yellow fever vaccine recommendations in Africa, 2011. Available at: [http://gamapserver.who.int/mapLibrary/Files/Maps/ITH\\_YF\\_vaccination\\_africa.png](http://gamapserver.who.int/mapLibrary/Files/Maps/ITH_YF_vaccination_africa.png). Accessed: June 2013
15. WHO. Yellow fever vaccine recommendations in the Americas, 2011 . Available at: [http://gamapserver.who.int/mapLibrary/Files/Maps/ITH\\_YF\\_vaccination\\_americas.png](http://gamapserver.who.int/mapLibrary/Files/Maps/ITH_YF_vaccination_americas.png). Accessed: June 2013
16. Sanofi Pasteur. Yellow Fever: A Major Concern For Public Health. March 2013. Available at: [www.sanofipasteur.com](http://www.sanofipasteur.com). Accessed May 2013.
17. How Brazil joined the quest for a yellow fever vaccine. Bull World Health Organ 2013;91:165–166
18. Yellow fever vaccination: The potential of dose-sparing to increase vaccine supply and availability. Available at: [www.path.org/publications/files/TS\\_vtg\\_yf\\_rpt.pdf](http://www.path.org/publications/files/TS_vtg_yf_rpt.pdf). Accessed: June 2013.
19. Khromava AY., et al. Yellow Fever vaccine: An updated assessment of advanced age as a risk factor for serious Events. Vaccine 23 (2005) 3256-3263
20. Breugelmans JG et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013 Apr 3;31(14):1819-29.
21. Roukens AH et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One. 2011;6(12):e27753.
22. Fiocruz: Brazilian Basic Child Vaccination Schedule. Available at: [http://www.fiocruz.br/bio\\_eng/cgi/cgilua.exe/sys/start.htm?sid=168](http://www.fiocruz.br/bio_eng/cgi/cgilua.exe/sys/start.htm?sid=168). Accessed June 2013
23. Nigeria inaugurates massive immunisation campaign against yellow fever. Available at: <http://www.ynaija.com/nigeria-inaugurates-massive-immunisation-campaign-against-yellow-fever/>. Accessed: June 2013
24. Boddington NL Evaluation of travel medicine practice by yellow fever vaccination centers in England, Wales, and Northern Ireland. J Travel Med. 2012 Mar-Apr;19(2):84-91.
25. Monath TP et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 7;364(14):1326-33.
26. GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc. Available at: <http://www.xcellerex.com/>. Accessed: June 2013
27. Schäfer B et al. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One. 2011;6(9):e24505.

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and "the spiral logo" are UK Registered Trademarks, 2009